BACKGROUND
The worldwide prevalence of obesity has more than doubled from 1980 to 2014. In 2014, more than 1.9 billion adults, 18 years and older, were overweight, meaning 39% of the population. Therefore, 38% of the male population and 40% of the female population worldwide were overweight. Overall, about 13% of the world's adult population (11% of men and 15% of women) were obese in 2014. 1 Most of the world's population lives in countries where overweight and obesity kills more people than those who are underweight. Also, 41 million children under the age of 5 years old were overweight or obese in 2014. 1 Contextualizing, overweight and obesity are defined as abnormal or excessive fat accumulation that presents a risk to health. A crude population measure of obesity is the body mass index (BMI), a person's weight (kilograms) divided by the square of his or her height (meters). A person with a BMI equal to or more than 25 is considered overweight, and with a BMI of 30 or more is generally considered obese.
Overweight and obesity are major risk factors for a number of chronic diseases, including diabetes, cardiovascular diseases and cancer. Once considered a problem only in high income countries, overweight and obesity are now dramatically on the rise in low-and middle-income countries, particularly in urban settings. 2 In the United Kingdom, prevalence of obesity amongst people over 16 years old is 24,8% and the prevalence of severe obesity is approximately 2,5% (3,2% for women and 1,7% for men), meanwhile 6,6% of American adults are severely obese.
2-5 At BMI ≥ 40 kg/m², obesity is considered a dangerous dysfunction, generally associated with many diseases.
5 Amongst the most frequent comorbities associated to obesity are systemic hypertension (SH) 6-7 and diabetes mellitus type II (DM). 8 The epidemic of obesity results in major health related consequences in different ethnic populations. There is increasing awareness of the role of obesity in the development of cardiometabolic disease in recent years.
9
The metabolic syndrome (MetS) is strongly linked to obesity, and is considered a constellation of interrelated risk factors of metabolic origin that are accompanied by increased risk for cardiovascular disease and DM. This collection of unhealthy body measurements and abnormal laboratory test results include atherogenic dyslipidemia, SH, glucose intolerance, proinflammatory state, and a prothrombotic state.
10,11
In 1988, Reaven described "a cluster of risk factors for diabetes and cardiovascular disease" and named it "Syndrome X". His main contribution was an introduction of the concept of insulin resistance. MetS is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic components that directly increases the risk of atherosclerotic cardiovascular disease, DM, and many others causes of mortality.
10,11 Over the years the name "Syndrome X" was substituted by "Metabolic Syndrome" and recently it became known as "Cardiometabolic Syndrome".
12-14 In the United States, age-adjusted MetS prevalence among adult population was estimated to be 24-25%. Similarly, the prevalence of MetS in 7 European countries was approximately 23%. And, it was estimated that 20%-25% of South Asians have developed MetS.
15-16
A widely used definition of this syndrome was originally released on the 23 Other studies also have shown the coexistence between these two pathologies.
24,26
The most important risk factor for OSA is obesity 27 , mainly due to the fat buildup in the high portion of the abdomen and cervical region. Approximately, 60 to 70% of patients that present OSA are obese. In addition, its incidence amongst patients that present degree 3 obesity is 12 to 30 times higher than in general population.
28
OSA is characterized by recurrent partial or complete upper airway obstruction episodes during sleep in the presence of respiratory effort, with consequent drop of oxyhemoglobin's saturation, leading to negative intrathoracic pressures and awakenings. 29 The gold standard for OSA's diagnosis is the basal nighttime polyssomnography (PSG), characterized by the simultaneous registering of physiological parameters during a night's sleep, analyzing its stages, the respiratory pattern, cardiovascular function and body movements.
29,30
Aside from the possibility that OSA identifies a group of patients with a cluster of vascular risk factors, there may be specific effects of OSA which further increase the cardiovascular consequences of this possible risk factor association. Thus, "syndrome X" may actually include OSA and could be better considered as "syndrome Z" (SyndZ).
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AIMS AND HYPOTHESIS
Study objectives
Primary objective
To determine the prevalence and severity of SyndZ in severely obese female patients on the waiting list for bariatric surgery, and whether the presence of SyndZ is correlated with age, BMI, and neck circumference.
Secondary objectives
To identify the presence of sleep disorders through the PSG in severely obese female patients on the waiting list for bariatric surgery. Our hypothesis is that there should be a correlation between the severity of Apnea/Hypopnea index (AHI) and the physiological and clinical variables from the patients involved in this study.
Methods and design
Study design and setting
A consecutive single-center cross-sectional study will be performed, to investigate the prevalence and severity of SyndZ in severely obese women. This study will be conducted in the Medical School of Santa Casa de Sao Paulo and at the Sleep Laboratory of the Nove de Julho University (UNINOVE). The design and conduct of this study followed the guidelines of the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement, according to figure 1.
Ethical and legal aspects
The study will be conducted in accordance with the ethical standards established in 1961 by Declaration of Helsinki (revised Hong Kong in 1989 and Edinburgh, Scotland, in 2000) and will be in accordance with the Regulatory Guidelines and Standards of Research Involving Human Subjects of Comissao Nacional de Etica em Pesquisa (CONEP) do Ministerio da Saude published in December, 2012. This protocol study has been approved by the Research Ethics Committee of the Nove de Julho University (Brazil), process no. 360.488 and is registered in the ClinicalTrials.gov no. NCT02409173. The signing of the free and informed consent will be required from all patients, and they will be allowed to withdraw from the study at any time without any negative consequences. Patients with severe clinical problems will be referred to the appropriate treatment aimed at their health status and quality of life.
Subjects and recruitment procedure
Female patients, with severe obesity on waiting list for bariatric surgery, according to the identification criteria (BMI between 40 kg / m² and 50 kg / m 2 or BMI between Figure 1 . Flow diagram of the study.
Prevalence of syndrome Z in severely obese 35 kg/m² and 39,9 kg/m² associated with comorbities) will be recruited from the surgery unit of the Santa Casa de Misericordia from the city of Sao Paulo (Brazil). The participants will be recruited consecutively and selected according to the eligibility criteria from standardized protocol. The eligibility criteria are as follow.
Eligibility criteria
The following inclusion criteria must be fulfilled at the start of the study: female patients, age of 18-65 years, stage III severe obesity (BMI of ≥40 kg/m2 or ≥35 kg/m2 with comorbities), awaiting BS, a documented history of failed conventional weight loss attempts, and the ability to understand and agree to participate in the study, based on a signed informed consent. The exclusion criteria will be BMI of >55 kg/m2, alcohol or drug abuse, cancer, and any other cardiorespiratory and/or medical condition that contraindicates participation in the study.
Clinical evaluation
The clinical evaluation of the patients included on this study will happen before bariatric surgery is held. All subjects will be submitted to the same evaluation protocol described subsequently. Evaluation will be done by a doctor and a physiotherapist, following standard recommended procedures and using precise instruments
32
, including body weight (kg), height (m), BMI, neck, hip and waist circumference (cm) 33 , respiratory and cardiac rates, arterial pressure, specific questionnaires for OSA and excessive daytime sleepiness (EDS) and a quality of life questionnaire. Some relevant clinical information will also be collected from patient's charts at the occasion of the first appointment.
Blood pressure will be measured between the hours of 8 and 11 a.m. after the patient will have rested in a sitting position for 5 minutes, using the sphygomanometer (Omron automatic oscillometric digital blood pressure monitor, model HEM-705CP, Omron Corporation, Tokyo, Japan) to obtain the systolic blood pressure (SBP) and diastolic blood pressure (DBP). The measurements will be obtained three times, and the average values will be used in the data analysis. The time in between measurements will be one minute.
Laboratorial analysis of blood's biochemistry
The analyses will be done through blood samples collection for the execution of complete hemogram, sodium and potassium dosage, glycaemia, creatinine, triglycerides, HDL cholesterol and total cholesterol. All samples will be collected in a laboratory of biochemical analyzes at hospital by a qualified technician and using disposable material, being followed the bio-security standards.
Fasting glucose
Fasting glucose will be measured after an overnight fast in whole blood using a glucose-oxidase-based assay (YSI 2300, Analytical Technologies, Farnborough, UK).
Insulin resistance
Insulin will be quantified using the IMMULITE 2000 Insulin assay, a solid-phase, two-site, chemiluminescent enzyme-labelled immunometric assay, and the Immulite 2000 automated analyser (Diagnostic Products Corporation, Los Angeles, CA, USA). Insulin resistance will be assessed from fasting glucose and insulin values using homeostasis model assessment (HOMA) calculations, previously validated against the hyperinsulinaemic euglycaemic clamp.
Lipids
Fasting cholesterol, triglyceride (Bayer Corporation, Tarrytown, NY, USA), and HDL cholesterol (Sigma Diagnostics, St. Louis, MO, USA) concentrations will be measured after an overnight fast using an immunocolourimetric assay on an ADVIA  1650 chemistry system (Bayer Corporation, Tarrytown, NY, USA). Low-densitylipoprotein (LDL) cholesterol will be derived using the Friedwald equation.
Waist and neck circumferences
Measurements from neck and waist circumferences will be done with the use of a metric tape of seven mm width. The measuring points will be standardized as following, according to scientific literature. For the waist's circumference, the measuring in the middle between the inferior border of the last rib and the iliac crest will be used, fixating the tape's zero point to the thorax from the axillary line's level which is going to be used (axillary, xiphoidian or abdominal). The neck's circumference will be taken horizontally on the cricoid cartillage.
34,35
Epworth Sleepiness Scale
The Epworth Sleep Scale (ESS) is a self applicable questionnaire, based in questions about situations of excessive sleepiness envolving daily activities. The subjects will be oriented to classify in a scale of 0 to 3 the probability of feeling sleepy or falling asleep in eight different sittuations. Being zero no probability of falling asleep at all, one small probability of it happening, two moderate probability and three high probability.
36,37
Berlin Questionnaire
The Berlin Questionnaire (BQ) is a clinical questionnaire of acknowledged efficacy on verifying risk for OSA. This instrumment is composed by ten items, organized in three categories relative to snore and OSA (containing 5 items), daytime sleepiness (4 items) SH and obesity (1 item). Any bolded answer is considered positive. The punctuation is divided in two categories in which category 1 is considered positive with two or more positive answers for questions 1 to 5. Category 2 is considered positive with two or more positive answers to questions 6 to 8 and category 3 is considered positive if the answer for question 9 is yes or the BMI is over 30 kg/m². Two or more positive categories indicate a high risk for OSA.
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Polysomnography
PSG will be performed using a digital system Alice 5 (version 3.1.2 Flaga, Hs. Medical Devices, Islândia), at the Nove de Julho University Sleep Laboratory. All recording sensors will be fixed to the patient in a non-invasive manner using tape or elastic bands. The following physiological variables will be monitored simultaneously and continuously: four channels for the electroencephalogram (EEG) (C3-A2, C4-A1, O1-A2, O2-A1), two channels for the electrooculogram, four channels for the surface electromyogram (muscle of the submentonian region, and anterior tibialis muscle), one channel for an electrocardiogram (derivation V1 modified), airflow detection via two channels through a thermocouple and nasal pressure cannula, respiratory effort of the thorax and of the abdomen via x-trace belts, snoring, and body position via Alice 5 sensors, and arterial oxygen saturation and heart rate (HR) via an Alice 5 oximeter. All PSG exams will be performed and sleep stages visually scored according to standardized criteria for investigating sleep disorders.
39,40 EEG arousals, sleep-related respiratory events, and leg movements will be scored in accordance with the criteria established by the American Academy of Sleep Medicine Manual for Scoring Sleep and Associated Events.
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Statistical analysis
Normally distributed data will be presented as means ± standard error of the mean, logarithmically transformed data as the geometric mean (95% confidence interval for the mean), skewed data as the median (interquartile range), and categorical data as the number (percentage). Demographic data will be compared using the 95% confidence interval for the difference in the mean, median, and percentage, as appropriate.
For the remaining analyses, normal, skewed, and categorical variables will be compared using the mean, median, and percentage difference (95% confidence interval for the difference) and by unpaired t tests, Mann-Whitney, and v2 tests using the sequential rejective Bonferroni procedure of Holm within each analysis to account for multiple testing. For variables that will be logarithmically transformed before analysis, comparisons will be made using the anti-logged differences (interpreted as the ratio of the geometric mean and 95% confidence interval for the ratio) and Bonferroni corrected t tests as previously described.
In order to determine whether OSA will be associated with the outcome variables independent of obesity and other known covariates, a regression analysis adjusted for age, BMI, smoking, and alcohol consumption will also be done. Waist circumference, percentage body fat, and fat mass were excluded as covariates because of their high correlation with BMI. Normally distributed, skewed, and log-transformed outcome data would be analysed using multiple linear regression and assumptions would be checked by inspection of the residuals. Categorical outcome data will be analysed using multiple binary logistic regression and assumptions will be checked with the Hosmer-Lemeshow goodness-of-fit test. Statistical analysis will be performed using SPSS version 10 (Chicago, IL, USA).
DISCUSSION
Running scientific evidences suggest that OSA contributes independently to the rise on cardiometabolic risks, alarming health professionals involved with this subject as for the presence of metabolic dysfunction. During the apneic event hypoxemia associated to hypercapnia occurs, with a consequent stimulation of the sympathetic nervous system causing peripheric vasoconstriction. In addition, a reduction of the negative intrathoracic pressure is observed, as well as a decrease of the cardiac pre-and post-charge. After restoration of the ventilatory flow, there is an increase on the circulating volume (pre-charge) on the validity of the vasoconstriction, leading to repetitive elevations of the arterial pressure (AP) during the night. Chronically, sustained elevations of the AP by stimulation of sympathetic activity can be observed, simultaneously there is decrease on parasympathetic activity, decrease of nitric oxide and release of endothelin. 42 The hyperaldosteronism can be a cause for resistant hypertension in patients with OSA. Activation of the renin-angiotensin, inflammation, resistance to insulin, decrease on baroreceptors' sensibility, endothelial dysfunction oxidative stress and hyperleptinemia can also be implicated on arterial hypertension's progress. 43 However, populational longitudinal studies are necessary to prove the causal relation of OSA and metabolic disturbances or the opposite, as well as multi-centric controlled randomized studies to confirm the beneficial effect of therapy with positive pressure on the airways on metabolic disturbs on subjects with OSA.
